Dexlansoprazole

Dexilant treats all grades of erosive esophagitis (EE) for up to 8 weeks, maintains healed EE / relieves heartburn up to 6 months in adults or 16 weeks at 12–17 years, and treats heartburn associated with symptomatic non-erosive GERD for 4 weeks. Each indication applies from age 12.

Selected current 30 / 60 mg delayed-release capsules are reviewed. An older brand formulation, compounded product or another PPI does not share this exact administration contract. No H.pylori eradication, Zollinger–Ellison or off-label infant recipe is supplied; ongoing treatment beyond studied durations requires individual reassessment.

For EE healing with Child-PughB impairment,30 mg once daily up to 8 weeks. No adjustment for mildA; not recommended in severeC. The reduction is specifically stated for the 60 mg EE-healing regimen, not a new universal 15 mg schedule. Take without regard to food. Take a missed dose when remembered unless the next is due; otherwise skip, resume on schedule and never take two doses together.

Swallow whole without chewing. If necessary open capsule onto 1 tablespoon applesauce, swallow intact granules immediately without chewing and do not save. Do not crush the granules or apply this instruction to an unreviewed formulation.

Selected instructions allow mixing capsule granules with 20 mL water, withdrawing the whole mixture, gently swirling and administering immediately; then rinse / administer 10 mL water twice. NG use requires≥16 French tube and catheter-tip syringe, delivering into the stomach with the same 20 mL mixture and two 10 mL flushes. Do not save mixtures. Other tubes, smaller calibers or continuous-feed protocols require separate verification.

Known formulation hypersensitivity and concurrent rilpivirine-containing products. Hypersensitivity reactions may include anaphylaxis, angioedema, bronchospasm, acute tubulointerstitial nephritis or urticaria. Other interaction precautions are not mechanically added to the formal contraindications list.

Selected current labels have no boxed warning. Pediatric, renal, hypersensitivity and interaction warnings remain clinically important.

Common adult trial events include diarrhea, abdominal pain, nausea, upper-respiratory infection, vomiting and flatulence; adolescents also commonly reported headache and throat / nasopharyngeal symptoms. Serious reactions described above are reported after marketing; frequencies and causality are not universally estimable. Do not compare raw rates across different PPI trials.

Rilpivirine-containing therapy is contraindicated; avoid nelfinavir and verify atazanavir / saquinavir instructions. Reduced gastric acidity can alter iron, selected oncology drugs, azole antifungals or mycophenolate absorption; review the other product’s instructions and transplant risk. No universal safe spacing rule is given.

Monitor warfarin INR / PT, digoxin concentrations and tacrolimus troughs when indicated. High-dose methotrexate may require temporary PPI withdrawal under the treatment team. Avoid rifampin / St John’s wort; CYP2C19 / CYP3A4 inhibitors / inducers can alter exposure. Selected clopidogrel interaction findings were not considered clinically important, but do not establish blanket compatibility for all antiplatelet regimens.

Coordinate temporary withdrawal at least 14 days before chromogranin A assessment and at least 30 days before a secretin-stimulation test per label. Consider confirmatory testing for a positive THC screening result. Do not independently stop treatment before testing; use the ordering clinician’s plan.

There are no dexlansoprazole human pregnancy studies sufficient to define risk. Observational lansoprazole data are limited and do not establish absence of risk; animal developmental findings require discussion of maternal benefit / fetal risk. Human milk presence and infant / production effects are unknown; assess breastfeeding benefits, maternal need and possible infant risk.

Safety / effectiveness is established at 12–17 years for selected indications, with 16 week EE-maintenance study limit. Below 12 it is unestablished; below 2 it is not recommended, including infant GERD where related lansoprazole efficacy was not demonstrated. Older trials found no overall difference but increased sensitivity is possible; exposure / half-life are somewhat higher.

No parent drug is recovered in urine and kidney impairment is not expected to meaningfully alter PK, but direct dexlansoprazole renal-impairment studies were not performed. No label numeric renal / dialysis adjustment is supplied; TIN still requires vigilance. Child-PughA requires no adjustment, B reduces EE-healing dose as above, C is not recommended.

Dexlansoprazole is the R-enantiomer of lansoprazole and inhibits parietal-cell H+/K+-ATPase, blocking the final acid-production step. Delayed-release granules preserve delivery; chewing changes the intended formulation.

Dual delayed release produces peaks at 1–2 and 4–5 hours; plasma half-life is around 1–2 hours. Hepatic metabolism through CYP2C19 / CYP3A4 produces inactive metabolites eliminated in urine / feces; protein binding is high. CYP2C19 phenotype changes exposure, but selected label data do not supply a genotype-based universal dose algorithm. The label’s food-independent administration instruction does not mean food has zero PK effect.

Follow symptom / healing response, adherence and continuing indication. Evaluate malignancy / red flags rather than rely on relief alone. Consider magnesium baseline / periodic checks with prolonged treatment, digoxin / diuretics or other risk; check magnesium / calcium in patients at hypocalcemia risk. Assess B12 symptoms and bone risk where appropriate; monitor interacting INR / drug levels and renal symptoms. No universal laboratory interval is invented.

Take once daily as directed regardless of food, preserve granules and follow the verified applesauce / syringe / NG method if needed. Do not double missed doses. Report persistent watery diarrhea, reduced urine, severe rash / blistering, allergy, cramps / palpitations or lupus-like symptoms. Inform the team about pregnancy, rilpivirine, methotrexate and planned diagnostic tests.

Seek medical / Poison Control help for excess dosing or significant symptoms. Care is symptomatic / supportive and dialysis is not expected to remove substantial drug. Selected high-dose study observations do not define a safe overdose amount or authorize higher routine dosing.

Product

Dexilant 30 mg delayed-release capsule

Route

Oral prescription capsule

Appearance

Opaque blue / gray; TAP /30

Example package

Bottle 30 · NDC 64764-171-30

Dexilant 30 mg blue / gray TAP 30 and 60 mg blue TAP 60;60 mg bottle 30 NDC 64764-175-30. Selected generic labeling describes 30 mg T 001 (blue / gray) and 60 mg T 002 (blue); its actual repackaged supplied bottle is 30 mg,30 capsules, NDC 71335-3071-1. Do not identify these from brand imprints. No older orally-disintegrating or other manufacturer’s product is asserted interchangeable on appearance.

Dexilant:20–25°C, excursions 15–30°C. Selected generic:20–25°C, excursions 15–30°C. Preserve intact granules; applesauce / water mixtures must be used immediately and not stored. Follow actual dispensing expiry; no compounded suspension shelf-life is invented.